Abstract
BackgroundImmunotherapies have improved the treatment landscape for recurrent and metastatic head and neck cancers (HNC). Immune checkpoint inhibitors (ICI) have led to durable benefit in approximately 20% of HNSCC patients....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
